CJC-1295

Mechanism of action: Long-acting GHRH receptor agonist; Increases pulsatile GH secretion; Raises circulating IGF-1 for several days

Proposed indications: Adult GH deficiency; Recovery from intense exercise; Muscle preservation; Body composition; Healthy aging

Reported dosing range*: 30 or 60 mcg/kg, subcutaneous (single ascending-dose study)

A pharmacokinetic study of this long-acting, DAC-conjugated form (half-life approximately 5.8-8.1 days) evaluated single ascending subcutaneous doses, identifying 30 and 60 mcg/kg as particularly well-tolerated (Teichman SL et al. (2006). Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism). This is a pharmacology study, not an efficacy trial for any specific outcome.

*General range reported in available research or other sources -- not an individualized recommendation. Actual use should be supervised by a qualified provider.

Typical clinical dosing schedule: No approved dosing regimen exists. Clinical studies have evaluated intermittent administration under research protocols.

Administration: Subcutaneous injection — No approved dosing regimen exists

Compare with: SermorelinTesamorelinIpamorelin

An "emerging / limited evidence" rating means rigorous research hasn't caught up yet -- not that this peptide doesn't work. Many peptides in this category are newer or simply understudied rather than proven ineffective.

Evidence rating: ⭐⭐☆☆☆ — Human studies demonstrate increased GH and IGF-1, but there is little evidence for meaningful clinical outcomes.

Landmark trials: Teichman SL, et al. (2006) — Demonstrated sustained GH and IGF-1 elevation following administration of CJC-1295 in healthy adults.

Common side effects: Injection-site reactions, Flushing, Headache, Water retention

Serious risks: Unknown long-term safety; Elevated IGF-1; Glucose intolerance; Possible increased cancer risk with chronic IGF-1 elevation

Monitoring: IGF-1, Blood glucose, Blood pressure, Clinical adverse effects

Legal status: Not FDA-approved for human use. This is a research compound, not a medication — any use should only occur under the direction of a licensed healthcare provider, and its legal availability varies and changes frequently. Verify current status independently before considering use.

Regulatory status: Research peptide • Not FDA approved

Contraindications: Unknown due to lack of approved labeling. Avoid use in:; Active cancer; Pregnancy; Severe endocrine disorders unless under specialist care

Pregnancy & breastfeeding: Avoid.

Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism.